Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Remon J, Reguart N, Campelo RG, et al. et al. Lung Cancer in Spain. J Thorac Oncol. 2020 Oct 24;16(2):197–204. Elsevier
   PubMedGoogle Scholar
• Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008 May 01;83(5):584–594. Elsevier
   PubMedGoogle Scholar
• Dearden S, Stevens J, Wu Y-L, et al. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013 Sep;24(9):2371–2376.
   PubMed Web of Science ®Google Scholar
• Reck M, Hagiwara K, Han B, et al. ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: the ASSESS Study. J Thorac Oncol. 2016 Oct;11(10):1682–1689.
   PubMed Web of Science ®Google Scholar
• Esteban E, Majem M, Martinez Aguillo M, et al. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: the Spanish REASON study. Cancer Epidemiol. 2015 Jun;39(3):291–297.
   PubMedGoogle Scholar
• Felip E, Stahel RA, Pavlidis N, et al. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol. 2005;16 Suppl 1:i28–i29.
   Google Scholar
• Ettinger DS,  Wood DE, Akerley W, et al. Non–Small Cell Lung Cancer, Version 1.2015. J National Compr Cancer Network. 2014 Dec;12(12):1738–1761.
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Marinis FD, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
   Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N Engl J Med. 2002 Jan;346(2):92–98.
   PubMed Web of Science ®Google Scholar
• Hsu W-H, Yang JC-H, Mok TS, et al. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018 Jan;29(suppl_1):i3–i9.
   PubMed Web of Science ®Google Scholar
• Aguiar F, Fernandes G, Queiroga H, et al. Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population. Arch Bronconeumol. 2018;54(1):Jan.
   Google Scholar
• Ghafoor Q, Baijal S, Taniere P, et al. Epidermal Growth Factor Receptor (EGFR) kinase inhibitors and Non-Small Cell Lung Cancer (NSCLC) - advances in molecular diagnostic techniques to facilitate targeted therapy. Pathol Oncol Res. 2018 Oct;24(4):723–731.
   PubMed Web of Science ®Google Scholar
• Gaut D, Sim MS, Yue Y, et al. Clinical Implications of the T790M mutation in disease characteristics and treatment response in patients with Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Clin Lung Cancer. 2018 Jan;19(1):e19–e28.
   PubMed Web of Science ®Google Scholar
• Elamin YY, Gomez DR, Antonoff MB, et al. Local Consolidation Therapy (LCT) after first line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC). Clin Lung Cancer. 2019 Jan;20(1):43–47.
   PubMed Web of Science ®Google Scholar
• Yun C-H, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008 Feb;105(6):2070–2075.
   PubMed Web of Science ®Google Scholar
• Cross DAE, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046–1061.
   PubMed Web of Science ®Google Scholar
• Goss G, Tsai C-M, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016 Dec;17(12):1643–1652.
   PubMed Web of Science ®Google Scholar
• Yang JC-H, Ahn M-J, Kim D-W, et al. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017 Apr;35(12):1288–1296.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 Feb;376(7):629–640.
   PubMed Web of Science ®Google Scholar
• Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018 Jan;378(2):113–125.
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct;29(Suppl 4): 863–870.
   Google Scholar
• ESMO. Clinical practice living guidelines – metastatic non-small-cell lung cancer. 2021 May 27 [cited 2021 May 27]. Available from: https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer
   Google Scholar
• Liang W, Wu X, Fang W, et al. Network meta-analysis of erlotinib, gefitinib, Afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PloS One. 2014 Feb;9(2):e85245.
   Google Scholar
• Zhang Y, Zhang Z, Huang X, et al. “Therapeutic efficacy comparison of 5 major EGFR-TKIs in advanced EGFR-positive non-small-cell lung cancer: a network meta-analysis based on head-to-head trials. Clin Lung Cancer. 2017 Sep;18(5):e333–e340.
   PubMedGoogle Scholar
• Holleman MS, Van Tinteren H, Groen HJ, et al. First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. Onco Targets Ther. 2019 Feb;12:1413–1421.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sheng J, Yang Y, et al. Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network meta-analysis. Oncotarget. 2016 Apr;7(15):20093–108.
   Google Scholar
• Popat S, Mok T, Yang JC-H, et al. Afatinib in the treatment of EGFR mutation-positive NSCLC–a network meta-analysis. Lung Cancer. 2014 Aug;85(2):230–238.
   PubMed Web of Science ®Google Scholar
• Batson S, Mitchell SA, Windisch R, et al. Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. Onco Targets Ther. 2017May;10:2473–2482.
   Google Scholar
• Franek J, Cappelleri JC, Larkin-Kaiser KA, et al. Systematic review and network meta-analysis of first-line therapy for advanced EGFR -positive non-small-cell lung cancer. Future Oncol. 2019 Aug;15(24):2857–2871.
   PubMed Web of Science ®Google Scholar
• Farris MS, Larkin-Kaiser KA, Scory T, et al. Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival. Future Oncol. 2020 Sep;16(36):3107–3116.
   PubMed Web of Science ®Google Scholar
• Lin J-Z, Ma S-K, Wu S-X, et al. A network meta-analysis of non-small-cell lung cancer patients with an activating EGFR mutation: should osimertinib be the first-line treatment? Medicine (Baltimore). 2018 Jul;97(30):e16824.
   Google Scholar
• Corral J, Espinàs JA, Cots F, et al. Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain). BMC Health Serv Res. 2015;15:70.
   PubMedGoogle Scholar
• Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018 Apr;27(4):746–761.
   PubMed Web of Science ®Google Scholar
• López Bastida J, Oliva J, Antoñanzas F, et al. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias. Gac Sanit. 2010;24(2):154–170.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al. “Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):Jan.
   Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun;362(25):2380–2388.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncology. 2010 Feb;11(2):121–128.
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Wu Y-L, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011 Jul;29(21):2866–2874.
   PubMed Web of Science ®Google Scholar
• Han J-Y, Park K, Kim S-W, et al. “First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012 Apr;30(10):1122–1128.
   PubMed Web of Science ®Google Scholar
• Park K, Tan E-H, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. The Lancet Oncology. 2016;17(5):577–589. May.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhou Q, Yan H, et al. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer. 2017 Jan 19;116(5):568–574. Springer Nature.
   PubMedGoogle Scholar
• Wu Y-L, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2017 Nov;18(11):1454–1466.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735–742.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. “Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239–246.
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhou C, Liam C, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015Jun 23;26(9):1883–1889.
   Google Scholar
• Zhou C, Wu Y, Chen G, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015 Jul 03;26(9):1877–1883.
   Google Scholar
• Sequist LV, Yang JC-H, Yamamoto N, et al. Phase III study of Afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep;31(27):3327–3334.
   PubMed Web of Science ®Google Scholar
• Wu Y-L, Zhou C, Hu C-P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):213–222.
   PubMed Web of Science ®Google Scholar
• Yang JCH, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Jan 12;16(2):141–151. Elsevier.
   PubMed Web of Science ®Google Scholar
• Mok TS. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. J Clin Oncol. 2018 Aug et al.;36(22):2244–2250.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Aug 19;361(10):947–957.
   PubMed Web of Science ®Google Scholar
• Dias S, Ades AE, Welton NJ, et al. Network meta-analysis for decision-making. Chichester (UK):John Wiley & Sons. 2018. 10:293–322.
   Google Scholar
• Rohatgi A. WebPlotDigitizer, Version 4.4. 2020 Nov 01. [cited 2021 May 01]. Available from: https://automeris.io/WebPlotDigitizer
   Google Scholar
• Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012 Feb;12(1):9.
   PubMed Web of Science ®Google Scholar
• Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC medical research methodology. Springer Nature; 2011 May 06 11:61.
   Google Scholar
• Depaoli S, Clifton JP, Cobb PR. Just Another Gibbs Sampler (JAGS): flexible software for MCMC implementation. J Educ Behav Stat. 2016 Sep 24;41(6):628–649. American Educational Research Association
   Google Scholar
• Spanish Healthcare Ministry. Drug prices. 2021. [cited 2021 May 01]. Available from: https://cima.aemps.es/cima/publico/lista.html
   Google Scholar
• Spanish Healthcare Ministry. Official discounts in drug prices. 2021. [cited 2021 May 01]. Available from: https://www.mscbs.gob.es/profesionales/farmacia/pdf/DeduccionesFebrero2021.pdf
   Google Scholar
• Osakidetza, the Basque Health Service. Rates for billing health and teaching services of the Basque health service for 2019. 2019. [cited 2021 May 01]. Available from: https://www.euskadi.eus/contenidos/informacion/osk_servic_para_empresas/es_def/adjuntos/tarifas_2019.pdf
   Google Scholar
• Isla D, De Castro J, Juan O, et al. Costs of adverse events associated with erlotinib or Afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. Clinicon Econ Outcomes Res. 2017 Dec;9:31–38.
   PubMed Web of Science ®Google Scholar
• Villa G, Hernández-Pastor LJ, Guix M, et al. Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain. Clin Transl Oncol. 2015 Jan;17(1):24–33.
   PubMedGoogle Scholar
• Nuño-Solinís R, Herrera Molina E, Librada Flores S, et al. Care costs and activity in the last three months of life of cancer patients who died in the Basque Country (Spain). Gac Sanit. 2017 Dec;31(6):524–530.
   PubMedGoogle Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008 Oct;6(1):84.
   PubMed Web of Science ®Google Scholar
• Nafees B, Lloyd AJ, Dewilde S, et al. Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017 Oct;13(5):e195–e203.
   PubMed Web of Science ®Google Scholar
• Barton GR, Briggs AH, Fenwick EAL. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health. 2008 Oct;11(5):886–897.
   PubMed Web of Science ®Google Scholar
• Carcedo Rodriguez D, Artola Urain T, Chinea Rodriguez A, et al. Cost-effectiveness analysis of defibrotide in the treatment of patients with severe veno-occlusive disease/sinusoidal obstructive syndrome with multiorgan dysfunction following hematopoietic cell transplantation in Spain. J Med Econ. 2021 Jan;24(1):628–636.
   PubMed Web of Science ®Google Scholar
• Navarro F, Martinez-Sesmero JM, Balsa A, et al. “Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain. Clin Rheumatol. 2020 Oct;39(10):2919–2930.
   Google Scholar
• Taxonera C, de Andrés-Nogales F, García-López S, et al. Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain. Expert Rev Pharmacoecon Outcomes Res. 2021 Feb;1–11.
   PubMedGoogle Scholar
• Padilla-Galo A, García-Ruiz AJ, Levy Abitbol RC, et al. Real-life cost-effectiveness of benralizumab in patients with severe asthma. Respir Res. 2021 Dec;22(1):1–14.
   PubMedGoogle Scholar
• Cameron D, Ubels J, Norström F. On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review. Glob Health Action. 2018 Jan;11(1):1447828.
   PubMed Web of Science ®Google Scholar
• Holleman MS, Al MJ, Zaim R, et al. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. Eur J Health Econ. 2020 Feb;21(1): 153–164.
   Google Scholar
• Aguiar PN, Haaland B, Park W, et al. Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non–small cell lung cancer. JAMA Oncol. 2018 May;4(8):1080.
   PubMed Web of Science ®Google Scholar
• Bertranou E, Bodnar C, Dansk V, et al. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer. J Med Econ. 2018 Feb;21(2):113–121.
   PubMed Web of Science ®Google Scholar
• Aguilar-Serra J, Gimeno-Ballester V, Pastor-Clerigues A, et al. Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis. J Comp Eff Res. 2019 Aug;8(11):853–863.
   PubMed Web of Science ®Google Scholar
• Cai H, Zhang L, Li N, et al. Cost-effectiveness of osimertinib as first-line treatment and sequential therapy for EGFR Mutation-positive non-small cell lung cancer in China. Clin Ther. 2019 Feb;41(2):280–290.
   PubMed Web of Science ®Google Scholar
• Wu B, Gu X, Zhang Q. Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy. J Thorac Oncol. 2018 Mar;13(2):184–193.
   PubMed Web of Science ®Google Scholar
• Wu B, Gu X, Zhang Q, et al. Cost-effectiveness of osimertinib in treating newly diagnosed, advanced EGFR-Mutation-positive non-small cell lung cancer. Oncologist. 2019 Mar;24(3):349–357.
   Google Scholar
• Yu Y, Luan L, Zhu F, et al. PCN164 COST-EFFECTIVENESS OF DACOMITINIB VS. GEFITINIB AS FIRST-LINE TREATMENT FOR EGFR MUTATION POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER IN CHINA. Value Health. 2019 Nov;22:S467–S468.
   PubMed Web of Science ®Google Scholar
• Miguel LS, Paquete AT, Alarcão J, et al. PCN136 cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR)-activating mutations in portugal. Value Health. 2020 Dec; 23(2): 1-5.
   Google Scholar
• Aguilar-Serra J, Gimeno-Ballester V, Pastor-Clerigues A, et al. Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis. J Comp Eff Res. 2021 Mar;10(4):325–335.
   PubMedGoogle Scholar
• Chouaid C, Luciani L, LeLay K, et al. Cost-effectiveness analysis of afatinib versus gefitinib for first-line treatment of advanced EGFR-mutated advanced non-small cell lung cancers. J Thorac Oncol. Oct 2017;12(10): 1496–1502.
   PubMedGoogle Scholar
• Wang H, Zeng C, Li X, et al. Cost-utility of Afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer. Future Oncol. 2019 Jan;15(2):181–191.
   PubMed Web of Science ®Google Scholar
• Kim Y-J, Oremus M, Chen HH, et al. Cost-effectiveness analysis of afatinib, erlotinib, and gefitinib as first-line treatments for EGFR mutation-positive non-small-cell lung cancer in Ontario, Canada. PharmacoEconomics. 2021 May;39(5):537–548.
   PubMed Web of Science ®Google Scholar
• Schulz C, Gandara D, Berardo CG, et al. Comparative efficacy of second- and subsequent-line treatments for metastatic NSCLC: a fractional polynomials network meta-analysis of cancer immunotherapies. Clin Lung Cancer. 2019 Nov;20(6):451–460.
   PubMedGoogle Scholar
• Noronha V, Joshi A, Gokarn A, et al. The importance of brain metastasis in EGFR mutation positive NSCLC patients. Chemother Res Pract. 2014;2014:1–4.
   Google Scholar
• Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR -mutated advanced non–small-cell lung cancer. J Clin Oncol. 2018 Aug;36(33):3290–3297.
   Web of Science ®Google Scholar
• Yang JCH, Kim S-W, Kim D-W, et al. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study. J Clin Oncol. 2020 Feb;38(6):538–547.
   Google Scholar